Table 1.

Demographics and clinical features of inflammatory bowel disease patients with mucosal changes indefinite for dysplasia

Characteristic	All cases(n = 44)	IND without progression (n = 33)	IND with progression (n = 11)	P-value
Age, yrs	46.6 ± 15.1	43.4 ± 14.0	56.2 ± 14.7	0.031
Male, n (%)	25 (56.8)	17 (51.5)	8 (72.7)	0.3
IBD type, n (%)				0.31
Ulcerative colitis	38 (86.4)	27 (81.8)	11 (100)
Crohn’s disease or indeterminate colitis	6 (13.6)	6 (18.2)	0 (0)
Extent colitis (pancolitis), n (%)	21 (47.7)	15 (45.5)	6 (54.5)	0.6
Primary sclerosing cholangitis, n (%)	8 (18.2)	5 (15.2%)	3 (27.3%)	0.39
No. of interval colonoscopy (IQR)	4.0 (1.3–7.0)	3.0 (1.0–7.0)	7.0 (2.0–10.0)	0.23
No. of total follow-up biopsies (IQR)	12.0 (7.0–29.0)	12.0 (5.5–22.0)	29.5 (9.8–41.5)	0.06
Duration of colitis, yrs (IQR)	7.5 (2.0–12.8)	8.0 (2.5–14.0)	4.0 (0–10.0)	0.3
p53 weak nuclear stain, % (IQR)	10.0 (3.0–27.5)	10.0 (1.5–20.0)	20.0 (3.0–35.0)	0.17
p53 strong nuclear stain, % (IQR)	1.0 (0–5.0)	1.0 (0–3.0)	3.0 (0–10.0)	0.13
p53 strong cytoplasm, % (IQR)	0 (0–8.8)	0 (0–7.5)	2.0 (0–20.0)	0.34
Composite p53 scorea (IQR)	20.0 (5.8–44.0)	18.0 (5.0–36.0)	35.0 (17.0–85.0)	0.1
Cytokeratin 7, % (IQR)	3.5 (0–27.5)	2.0 (0–35.0)	8.0 (0–20.0)	0.81
Time to progression or last follow-up, months (IQR)	95.2 (42.4–129.2)	100.5 (54.4–134.1)	66.1 (24.7–86.1)	0.11
Time to last follow-up, months (IQR)	100.8 (62.7–135.7)	100.5 (54.4–134.1)	122.9 (66.1–145.0)	0.44

^aA composite p53 score for each case was obtained by the sum of (i) the percentage of cells with weak nuclear staining, (ii) three times the percentage of cells with strong nuclear staining, and (iii) the percentage of cells with strong cytoplasmic staining.

CD = Crohn’s disease; IBD = inflammatory bowel disease; IC = indeterminate colitis; IND = indefinite for dysplasia; UC = ulcerative colitis